Results for this period
Third quarter1 January 2026 to 30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Although there was no operating revenue, the company recorded ¥369.385 million in research and development expenses and ¥221.000 million in other selling, general and administrative expenses, bringing total operating expenses to ¥590.386 million.
No applicable matters (none applicable)
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 January 2026 to 30 September 2026 |
| Operating profit | -590 Millions of yen |
| Ordinary income | -590 Millions of yen |
| Profit attributable to owners of the parent | -601 Millions of yen |
| Net income per share | -¥13.05 |
| Equity ratio | End of the current fiscal period 94.2 / End of previous period 95.5 |
| Total assets | 2,593 Millions of yen |
| Net assets | 2,491 Millions of yen |
| Annual Dividend Forecast | 0 Yen → 0 Yen（0.0%） |
| Depreciation and amortization | 889 Thousands of yen |
| Impairment loss | 9,737 Thousands of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses 9,737 Thousands of yen |
| Disclosure regarding the going concern assumption | No applicable matters (none applicable) |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Material subsequent events | The investigation period for the clinical trial plan notification for TMS-008 ended on 14 October 2026. On 29 October 2026, the company entered into a term sheet with TME Pharma A.G. concerning the in-licensing of NOX-A12 and secured exclusive negotiating rights, but execution of the definitive agreement is not guaranteed. |
| Availability of Supplementary Financial Results Materials | None |
| Availability of Financial Results Briefing | None |
| Issued Shares at Period-End | 48,458,467 |
| Treasury Shares at Period-End | 10 |
| Factors Behind Changes in Business Performance | Although there was no operating revenue, the company recorded ¥369.385 million in research and development expenses and ¥221.000 million in other selling, general and administrative expenses, bringing total operating expenses to ¥590.386 million. |
Items this document does not state (15)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although there was no operating revenue, the company recorded ¥369.385 million in research and development expenses and ¥221.000 million in other selling, general and administrative expenses. The company states that it is in an upfront investment phase, advancing research and development without any products on the market, and that its performance is significantly affected by milestone payments and other revenue from licensing partners, making it difficult to formulate an earnings forecast.